Using modified immune cells to fight HIV
Activated NK CAR Cells to Cure HIV
This study is looking at a new way to boost the immune system's ability to fight HIV by using specially modified natural killer cells that can better find and destroy HIV-infected cells, especially in hard-to-reach areas of the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11056117 on NIH RePORTER |
What this research studies
This research investigates how to enhance the immune response against HIV by using modified natural killer (NK) cells that are specifically designed to target and eliminate HIV-infected cells. The approach focuses on increasing the presence of these immune cells in areas of the body where the virus replicates, particularly in B-cell follicles. By improving the ability of these modified NK cells to reach and act within these immune privileged sites, the research aims to achieve a more effective and lasting control of HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not achieved viral suppression with standard treatments.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that helps patients achieve long-term remission from HIV without the need for continuous antiretroviral therapy.
How similar studies have performed: Other research has shown promise in using modified immune cells for cancer treatment, suggesting that similar approaches may be effective for HIV, although this specific application is novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Skinner, Pamela J — University of Minnesota
- Study coordinator: Skinner, Pamela J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.